News

NORTH CHICAGO, Ill., Sept. 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from several clinical studies evaluating potential new medicines in the company's oncology pipeline will be presented at the upcoming 2014 European Society of Medical Oncology (ESMO) Annual Congress, September 26-30, in Madrid, Spain. Data being presented include results from a Phase 2 study evaluating the safety and efficacy of veliparib (ABT-888), a poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor, in combination with two broad-acting chemotherapeutic medicines in patients with non-small cell lung cancer (NSCLC).

Results from a Phase 1 study of ABT-414, an anti-EGFR (epidermal growth factor receptor) monoclonal antibody drug conjugate, in patients with newly diagnosed glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor, will also be presented during an oral presentation.

"The presentations at ESMO highlight AbbVie's continued commitment to developing potential new medicines for patients with prevalent cancers who have few treatment options," said Gary Gordon, M.D., vice president, oncology clinical development, AbbVie. "At AbbVie, we have implemented innovative approaches to developing compounds that inhibit cellular reproduction and induce programmed cell death, which could potentially provide additional options for treating patients across many types of cancer."

Meeting abstracts are available at http://www.esmo.org/Conferences/ESMO-2014-Congress/Abstracts.  

AbbVie's abstract presentations include:

Veliparib (ABT-888)

• A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) with Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer; S.S. Ramalingam, et al.; Abstract 1234;  September 27, 2014; Poster Display Session –  12:45-1:45 p.m. Central European Summer Time
• A Phase 1 Study of Veliparib (ABT-888) in Combination with Carboplatin/Paclitaxel in Japanese Subjects with Non-Small Cell Lung Cancer (NSCLC); H. Mizugaki, et al.; Abstract 1213; September 27, 2014; Poster Display Session –  12:45-1:45 p.m. Central European Summer Time

ABT-414

• A Phase 1 Study Evaluating ABT-414 with Concurrent Radiotherapy (RT) and Temozolomide (TMZ) in Newly Diagnosed Glioblastoma (GBM); H.K. Gan, et al.; Abstract 416; September 27, 2014; Oral Presentation –  2:30 p.m., Profferred Papers – 2:00-3:45 p.m. Central European Summer Time

ABT-767

• A Study of ABT-767 in advanced solid tumors with BRCA 1 and BRCA 2 Mutations and High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; De Jonge et al.; Abstract 452; September 27, 2014; Poster Display Session – 12:45-1:45 p.m. Central European Summer Time

About Veliparib (ABT-888)
Veliparib is an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor being evaluated in multiple tumor types. PARP is a naturally-occurring enzyme in the body that repairs damage to DNA, and in certain types of cancers, repairs cancer cells. Discovered by AbbVie researchers, veliparib is being developed to help prevent DNA repair in cancer cells and increase the effectiveness of common DNA-damaging therapies like chemotherapy or radiation. Veliparib is currently being studied in more than a dozen cancers and tumor types, including Phase 3 studies in non-small cell lung cancer and breast cancer. Veliparib is an investigational compound and its efficacy and safety have not been established by the FDA.

About ABT-414
ABT-414 is an investigational anti-EGFR (epidermal growth factor receptor) monoclonal antibody drug conjugate (ADC) being evaluated for the treatment of patients with various cancer and tumor types. As an ADC, ABT-414 is designed to be stable in the bloodstream and only release the potent cytotoxic agent once inside targeted cancer cells. Developed by AbbVie researchers with components in-licensed from Life Sciences Pharmaceuticals, Inc. and Seattle Genetics, ABT-414 is currently being investigated for the treatment of glioblastoma multiforme, the most common and most aggressive malignant primary brain tumor. ABT-414 is also in clinical trials for the treatment of patients with squamous cell tumors, including non-small cell lung cancer. ABT-414 is an investigational compound and its efficacy and safety have not been established by the FDA.

About ABT-767
ABT-767 is an investigational poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor being evaluated in multiple tumor types. PARP is a naturally-occurring enzyme in the body that repairs damage to DNA, and in certain types of cancers, repairs cancer cells. ABT-767 is currently being investigated in an ongoing Phase I clinical trial in patients with a variety of solid tumors. ABT-767 is an investigational compound and its efficacy and safety have not been established by the FDA.

About AbbVie Oncology
AbbVie's oncology research is focused on the discovery and development of targeted therapies that work against the processes cancers need to survive. By investing in new technologies and approaches, we are breaking ground in some of the most widespread and difficult-to-treat cancers, including multiple myeloma and chronic lymphocytic leukemia. Our oncology pipeline includes multiple new molecules in clinical trials being studied in more than 15 different cancers and tumor types. For more information on AbbVie Oncology and our oncology portfolio, please visit http://oncology.abbvie.com.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

SOURCE AbbVie